Rhumbline Advisers Sells 19,272 Shares of Sotera Health (NASDAQ:SHC)

Rhumbline Advisers lessened its holdings in Sotera Health (NASDAQ:SHC) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 315,253 shares of the company’s stock after selling 19,272 shares during the quarter. Rhumbline Advisers owned 0.11% of Sotera Health worth $3,742,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC boosted its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares in the last quarter. Sandia Investment Management LP bought a new stake in shares of Sotera Health in the 1st quarter valued at about $120,000. Securian Asset Management Inc. increased its stake in shares of Sotera Health by 23.0% in the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock valued at $122,000 after acquiring an additional 1,900 shares during the last quarter. Wedmont Private Capital bought a new stake in Sotera Health during the 2nd quarter worth approximately $127,000. Finally, Simplicity Wealth LLC bought a new stake in Sotera Health during the 2nd quarter worth approximately $128,000. Institutional investors own 91.03% of the company’s stock.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 55.12% of the company’s stock.

Sotera Health Stock Up 0.7 %

Shares of NASDAQ SHC opened at $16.91 on Tuesday. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The stock’s fifty day moving average is $14.50 and its 200 day moving average is $12.77. The stock has a market capitalization of $4.79 billion, a P/E ratio of 89.00 and a beta of 2.07.

Sotera Health (NASDAQ:SHC) last released its earnings results on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The firm had revenue of $277.00 million for the quarter, compared to analysts’ expectations of $266.45 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Sell-side analysts forecast that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SHC has been the subject of several research reports. Piper Sandler assumed coverage on shares of Sotera Health in a research note on Tuesday, May 21st. They set a “neutral” rating and a $13.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Finally, Barclays raised their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.70.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.